Net Asset Value(s)

RNS Number : 0563J

Port Erin Biopharma Investments Ltd

11 July 2013

 



Port Erin Biopharma Investments Limited

 (the "Company")

Net Asset Value calculation to 30 June 2013

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2013 was 10.63 pence per share, including un-invested cash of £707,624. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a decrease of 5.3% from the previous valuation of 11.22 pence per share, which included un-invested cash of £287,310. However, the combined value of investments and cash at £3.625 million represents a fall of only 2.6% on the same value last period. The revenue reserve at £0.84 million still represents a return of over 33.3% on investments after listing and operating costs."

		Unaudited to 30 June 2013 £
Fixed Assets
	Investments	2,916,930
Current Assets
	Debtors: amounts owing	7,797
	Un-invested cash	707,624
Current Liabilities
	Creditors: amounts due	(32,400)
		3,599,951
Capital and Reserves
	Share Capital	34
	Share Premium	2,759,551
	Current year's earnings	415,158
	Retained earnings	425,208
		3,599,951
Shares in Issue		33,864,836
Net Asset Value per share		10.63 pence

--- ENDS ---

Portfolio Details

Investments Schedule at 30 June 2013	£ Valuation	Portfolio %
Synergy Pharmaceuticals Inc.	277,748	9.52%
Summit Corporation plc	212,500	7.29%
Arrowhead Research	207,364	7.11%
Plethora Solutions Holdings plc	166,625	5.71%
TrovaGene Inc.	137,224	4.70%
Pfizer Inc.	136,562	4.68%
Nektar Therapeutics	127,303	4.36%
Sanofi-ADR	91,349	3.13%
	1,356,675	46.51%
Aggregate value of remaining holdings below 3% of total portfolio	1,560,255	53.49%
TOTAL INVESTMENTS	2,916,930	100.00%

For further information, please contact:

Port Erin Biopharma Investments Ltd	Libertas Capital Corporate Finance Limited	Peterhouse Capital Limited
The Company	Nomad	Broker
Denham Eke [phone]	Sandy Jamieson [phone]	Jon Levinson [phone]

 

END

 

 

NAVDMGMNKGLGFZM